Abstract
A 13-month-old Japanese female with Haemophilus influenzae type b meningitis presented with unusually severe septic shock and cerebral infarction in half a day of fever. The initial therapy of plasma-derived activated protein C (Anact C®) led to an impressive effect on the aggressive condition. However, purpura fulminans and the consistent decline of plasma protein C activity (<20%) required prolonged activated protein C therapy and gene analysis. The patient carried a novel heterozygous mutation of PROC (exon 4; 335 GAC>TAC, Asp46Tyr). This is the first report of infectious purpura fulminans in a protein C-deficient heterozygote. The clinical onset and treatment course adequately corroborated the aggravated immune/hemostatic reactions and the cytoprotective effects of activated protein C replacement in human heterozygous protein C deficiency. The monitoring of plasma protein C activity and sufficient administration of activated protein C product could improve the outcome of severe sepsis in children.
Similar content being viewed by others
Abbreviations
- aPC:
-
Activated protein C
- APTT:
-
Activated partial thromboplastin time
- CSF:
-
Cerebrospinal fluid
- CRP:
-
C-reactive protein
- CT:
-
Computed tomography
- DIC:
-
Disseminated intravascular coagulopathy
- FVL:
-
Factor V Leiden
- FDP:
-
Fibrinogen and fibrin degradation products
- Hib:
-
Haemophilus influenzae type b
- PC:
-
Protein C
- PIC:
-
Plasmin α2–antiplasmin complex
- PS:
-
Protein S
- PT:
-
Prothrombin time
- SIRS:
-
Systemic inflammatory response syndrome
- TAT:
-
Thrombin–antithrombin complex
References
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709
Betrosian AP, Berlet T, Agarwal B (2006) Purpura fulminans in sepsis. Am J Med Sci 332:339–345
Childers BJ, Cobanov B (2003) Acute infectious purpura fulminans: a 15-year retrospective review of 28 consecutive cases. Am Surg 69:86–90
Dollberg S, Nachum Z, Klar A, Engelhard D, Ginat-Israeli T, Hurvitz H et al (1992) Haemophilus influenzae type b purpura fulminans treated with hyperbaric oxygen. J Infect 25:197–200
Ganopolsky JG, Castellino FJ (2004) A protein C deficiency exacerbates inflammatory and hypotensive responses in mice during polymicrobial sepsis in a cecal ligation and puncture model. Am J Pathol 165:1433–1446
Gast T, Kowal-Vern A, An G, Hanumadass ML (2006) Purpura fulminans in an adult patient with Haemophilus influenzae sepsis: case report and review of the literature. J Burn Care Res 27:102–107
Goldstein B, Nadel S, Peters M, Barton R, Machado F, Levy H et al (2006) ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis. Pediatr Crit Care Med 7:200–211
Gürgey A, Aytac S, Kanra G, Secmeer G, Ceyhan M, Altay C (2005) Outcome in children with purpura fulminans: report on 16 patients. Am J Hematol 80:20–25
Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR et al (2003) Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 102:3085–3092
Kinoshita S, Iida H, Inoue S, Watanabe K, Kurihara M, Wada Y et al (2005) Protein S and protein C gene mutations in Japanese deep vein thrombosis patients. Clin Biochem 38:908–915
Lay AJ, Donahue D, Tsai MJ, Castellino FJ (2007) Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood 109:1984–1991
Levi M, Dörffler-Melly J, Reitsma P, Buller H, Florquin S, van der Poll T et al (2003) Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood 101:4823–4827
Mosnier LO, Zlokovic BV, Griffin JH (2007) The cytoprotective protein C pathway. Blood 109:3161–3172
Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL et al (2007) Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 369:836–843
Nguyên P, Reynaud J, Pouzol P, Munzer M, Richard O, François P (1994) Varicella and thrombotic complications associated with transient protein C and protein S deficiencies in children. Eur J Pediatr 153:646–649
Sakata T, Kario K, Katayama Y, Matsuyama T, Kato H, Miyata T (2000) Studies on congenital protein C deficiency in Japanese: prevalence, genetic analysis, and relevance to the onset of arterial occlusive diseases. Semin Thromb Hemost 26:11–16
Santamaria JP, Kenney S, Stiles AD (1985) Purpura fulminans associated with Haemophilus influenzae type B infection. N C Med J 46:516–517
Shorr AF, Nelson DR, Wyncoll DL, Reinhart K, Brunkhorst F, Vail GM, Janes J (2008) Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). Crit Care (in press)
Venkataseshan S, Dutta S, Ahluwalia J, Narang A (2007) Low plasma protein C values predict mortality in low birth weight neonates with septicemia. Pediatr Infect Dis J 26:684–688
Acknowledgments
This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan, and by a research grant from the Japan Society for the Promotion of Science (JSPS).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ishimura, M., Saito, M., Ohga, S. et al. Fulminant sepsis/meningitis due to Haemophilus influenzae in a protein C-deficient heterozygote treated with activated protein C therapy. Eur J Pediatr 168, 673–677 (2009). https://doi.org/10.1007/s00431-008-0816-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-008-0816-9